Cas:15790-94-0 trans-2-Undecenoic acid manufacturer & supplier

Chemical Name:trans-2-Undecenoic acid

CAS.NO:15790-94-0

Synonyms:2-UNDECENOIC ACID;trans-2-undecenoic acid;TRANS-2-UNDECENOIC ACID: TECH.;(E)-undec-2-enoic acid;trans-2-Undecenoic acid, tech. 80%;trans-2-Undecylenic acid;MFCD00040909;2-undecylenic acid;RARECHEM AL BK 0167;n-undecylenic acid;trans-2-undecanoic acid;(E)-2-Undecenoic acid;(2E)-2-Undecenoic acid

Molecular Formula:C₁₁H₂₀O₂

Molecular Weight:184.27500

HS Code:2916190090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:295.4ºC at 760mmHg

Density:0.929g/cm3

Index of Refraction:1.4625

PSA:37.30000

Exact Mass:184.14600

LogP:3.37780

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-UNDECENOIC ACID chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(2E)-2-Undecenoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(E)-undec-2-enoic acid Use and application,n-undecylenic acid technical grade,usp/ep/jp grade.

Related News: By recapitulating the tumor microenvironment and using a live-cell, function-first approach, Resonant��s platform generates therapeutic candidates that would not be discovered by other methods with unprecedented speed. trans-2-Undecenoic acid manufacturer The iLet is designed to function as three medical devices in one. It can be configured as an insulin-only bionic pancreas, a glucagon-only bionic pancreas, or a bihormonal bionic pancreas using insulin and glucagon. trans-2-Undecenoic acid supplier The iLet is designed to function as three medical devices in one. It can be configured as an insulin-only bionic pancreas, a glucagon-only bionic pancreas, or a bihormonal bionic pancreas using insulin and glucagon. trans-2-Undecenoic acid vendor The results of analysis perfectly align with the tau hypothesis — simply put, if the patient is tau biomarker positive, then tau pathology is responsible for his/her cognitive decline, and halting tau pathology should slow or halt progression,” Novak said. “If the patient is negative for markers of tau pathology, then this patient’s impairment is mainly due to other pathologies, and treating tau pathology in this patient won’t be meaningful. trans-2-Undecenoic acid factory First up is Lilly, which reached all-time highs this week as attention turned to its once highly hyped donanemab, another anti-amyloid that saw a mixed bag of data back in March, with a slight win on one disease scale undermined by a failure on a more widely used measure of Alzheimer’s.